Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer.

Sci Rep · 2025 · PMC12316914 · PMID 40750803

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The GEICAM-9401 and SWOG-8814 studies showed a trend to inferior survival outcomes with concurrent tamoxifen and chemotherapy, but the results were not statistically significant in either study. 16 , 17 An Italian randomized trial evaluated concurrent or sequential tamoxifen administration with anthracycline-based adjuvant chemotherapy and suggested

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.